billHR8240•Event Thursday, April 9, 2026Analyzed

SAFER Act of 2026

Neutral

Summary

The SAFER Act of 2026 (HR8240) is an early-stage immigration bill referred to the House Judiciary Committee. It amends asylum law to bar grants of asylum to applicants who return to their country of concern, with narrow national security exceptions. No direct market impact is identifiable as the bill does not authorize spending, target specific industries, or create contract opportunities.

See which stocks are affected

Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.

Already have an account? Log in

Key Takeaways

1.HR8240 is an early-stage immigration bill with no funding or market mechanism.
2.No publicly traded companies are affected by this legislation.
3.The bill has low legislative momentum: one sponsor, one cosponsor, no Senate companion, and no committee action since introduction.

Market Implications

There are no market implications from this bill. It does not authorize spending, create contracts, or alter the regulatory landscape for any industry. Retail investors should ignore this legislation as it has no bearing on stock prices or sector performance.

Full Analysis

On April 9, 2026, Rep. Thomas Tiffany (R-WI-7) introduced HR8240, the SAFER Act of 2026, which was referred to the House Committee on the Judiciary. The bill amends Section 208 of the Immigration and Nationality Act to prohibit the Secretary of Homeland Security or the Attorney General from granting asylum to any alien who has returned to a country of concern (defined as the alien's country of nationality or last habitual residence for which asylum was sought). It also subjects those already granted asylum who return to such a country to termination of asylum, denaturalization, and applicable grounds of inadmissibility or deportability. A waiver is available only if the President certifies national security travel or the Secretary of State certifies a legitimate transfer of power in that country.

The bill is in the earliest legislative stage—introduced and referred to committee—with no further action in over two months. It has only one cosponsor and no companion bill in the Senate. The legislative path requires committee markup, House floor vote, Senate passage, and presidential action. Given the current session (119th Congress, 2025–2027) and the bill's narrow focus on asylum procedures, it faces significant hurdles and is unlikely to advance quickly or at all.

This bill does not authorize or appropriate any funding. It imposes a regulatory condition on asylum eligibility, which does not create or alter any market for goods or services. No publicly traded company is directly affected by this legislation. The policy area is immigration enforcement, not commerce, defense, or technology.

Because the bill has no financial mechanism, no sector or company is impacted. The analysis yields no tickers, no causal chains, and a neutral sentiment with a low impact score.